Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Sickle Cell Disease · Sickle Cell Anemia in Children
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mulago Hospital Sickle Cell Clinic, Kampala, Uganda
Contact: Study coordinator (Grace Ndeezi, MD, MMED PhD)
Study leads
Russell E. Ware, MD, PhD
Principal Investigator
Children's Hospital Medical Center, Cincinnati